{"brief_title": "A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder", "brief_summary": "This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.", "condition": "Major Depressive Disorder", "intervention_type": "Drug", "intervention_name": "Antidepressant + Aripiprazole", "description": "Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.", "arm_group_label": "A2", "other_name": "Abilify", "criteria": "Inclusion Criteria: - Men and women, 18-65 years old - Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks in duration. - Treatment history of an inadequate response to at least one and no more than three antidepressants.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "id": "NCT00095758.xml"}